Alpha 2.0
Login Register
» Authors » David J Ehresman

David J Ehresman

Explore the profile of David J Ehresman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 1465
Followers 0
Related Specialties
Toxicology
Environmental Health
Reproductive Medicine
Top 10 Co-Authors
John L Butenhoff
Shu-Ching Chang
Geary W Olsen
Jeffrey M Peters
George A Parker
Patricia E Noker
Kendall B Wallace
Gregory S Gorman
James A Bjork
Christopher Lau
Published In
Toxicol Sci
Toxicology
Reprod Toxicol
Environ Res
Environ Health Perspect
Affiliations
Soon will be listed here.
Recent Articles
1.
Perfluorooctane Sulfonate-Induced Hepatic Steatosis in Male Sprague Dawley Rats Is Not Attenuated by Dietary Choline Supplementation
Bagley B, Chang S, Ehresman D, Eveland A, Zitzow J, Parker G, et al.
Toxicol Sci . 2017 Oct; 160(2):284-298. PMID: 28973659
Perfluorooctane sulfonate (PFOS) is an environmentally persistent chemical. Dietary 100 ppm PFOS fed to male mice and rats for 4 weeks caused hepatic steatosis through an unknown mechanism. Choline deficient...
2.
Four-week dietary supplementation with 10- and/or 15-fold basal choline caused decreased body weight in Sprague Dawley rats
Bagley B, Chang S, Ehresman D, Eveland A, Parker G, Peters J, et al.
Toxicol Ind Health . 2017 Sep; 33(10):792-801. PMID: 28901218
Choline is an essential nutrient utilized for phosphatidylcholine biosynthesis and lipoprotein packaging and secretion. Recently, choline supplementation has been used by athletes and the public for weight loss. However, the...
3.
Perfluorooctanesulfonate (PFOS) Conversion from N-Ethyl-N-(2-hydroxyethyl)-perfluorooctanesulfonamide (EtFOSE) in male Sprague Dawley rats after inhalation exposure
Chang S, Mader B, Lindstrom K, Lange C, Hart J, Kestner T, et al.
Environ Res . 2017 Mar; 155:307-313. PMID: 28260617
Ethyl-N-(2-hydroxyethyl)-perfluorooctanesulfonamide (EtFOSE) was one of the key building blocks for many of the perfluorooctanesulfonyl-based chemistry and laboratory studies have shown that EtFOSE can metabolically degrade to perfluorooctanesulfonate (PFOS). Non-occupational contribution...
4.
Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS
Chang S, Allen B, Andres K, Ehresman D, Falvo R, Provencher A, et al.
Toxicol Sci . 2017 Jan; 156(2):387-401. PMID: 28115654
An oral dose study with perfluorooctanesulfonate (PFOS) was undertaken to identify potential associations between serum PFOS and changes in serum clinical chemistry parameters in purpose-bred young adult cynomolgus monkeys (Macaca...
5.
Organic Anion Transporting Polypeptides Contribute to the Disposition of Perfluoroalkyl Acids in Humans and Rats
Zhao W, Zitzow J, Weaver Y, Ehresman D, Chang S, Butenhoff J, et al.
Toxicol Sci . 2016 Dec; 156(1):84-95. PMID: 28013215
Perfluoroalkyl sulfonates (PFSAs) such as perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) have very long serum elimination half-lives in humans, and preferentially distribute to serum and liver. The enterohepatic circulation...
6.
Editor's Highlight: Perfluorooctane Sulfonate-Choline Ion Pair Formation: A Potential Mechanism Modulating Hepatic Steatosis and Oxidative Stress in Mice
Zhang L, Krishnan P, Ehresman D, Smith P, Dutta M, Bagley B, et al.
Toxicol Sci . 2016 Jul; 153(1):186-97. PMID: 27413108
The mechanisms underlying perfluorooctane sulfonate (PFOS)-induced steatosis remain unclear. The hypothesis that PFOS causes steatosis and other hepatic effects by forming an ion pair with choline was examined. C57BL/6 mice...
7.
Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats
Zhao W, Zitzow J, Ehresman D, Chang S, Butenhoff J, Forster J, et al.
Toxicol Sci . 2015 May; 146(2):363-73. PMID: 26001962
Among the perfluoroalkyl sulfonates (PFASs), perfluorohexane sulfonate (PFHxS), and perfluorooctane sulfonate (PFOS) have half-lives of several years in humans, mainly due to slow renal clearance and potential hepatic accumulation. Both...
8.
Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid
Yao P, Ehresman D, Caverly Rae J, Chang S, Frame S, Butenhoff J, et al.
Toxicology . 2014 Dec; 326:62-73. PMID: 25456267
Previous studies suggested that perfluorooctanoate (PFOA) could activate the estrogen receptor (ER). The present study examined the hypothesis that PFOA can activate ER using an in vivo uterotrophic assay in...
9.
A species difference in the peroxisome proliferator-activated receptor α-dependent response to the developmental effects of perfluorooctanoic acid
Albrecht P, Torsell N, Krishnan P, Ehresman D, Frame S, Chang S, et al.
Toxicol Sci . 2012 Nov; 131(2):568-82. PMID: 23143925
This study examined the effect of prenatal perfluorooctanoic acid (PFOA) administration on pre- and postnatal development using peroxisome proliferator-activated receptor α (PPARα)-humanized mice to determine if species differences in receptor...
10.
Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities
Olsen G, Ehresman D, Buehrer B, Gibson B, Butenhoff J, Zobel L
J Occup Environ Med . 2012 Jul; 54(8):974-83. PMID: 22842914
Objective: To examine in a longitudinal occupational assessment whether changes in serum concentrations of perfluorooctanoic acid (PFOA) and perfluorooctanesulfonate (PFOS) are associated with changes in non-high-density lipoprotein (HDL) cholesterol. Methods:...